Sandoz Walks Away From Rituxan Biosimilar in the U.S.

Drug Industry Daily
A A
Novartis subsidiary Sandoz abandoned its pursuit of U.S. approval for its biosimilar of Roche’s blockbuster cancer drug Rituxan (rituximab) and said it plans to focus on other products in the biosimilar pipeline.

To View This Article:

Login

Subscribe To Drug Industry Daily